Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026
